Drug Trial Radar · NCT05425940
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
901
Actual
Start
Sep 7, 2022
Primary completion
Jun 16, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Conditions
- Colorectal Cancer
Interventions
XL092Drug
Supplied as tablets; administered orally daily.
AtezolizumabDrug
Supplied as 1200 milligrams (mg)/20 milliliter (mL) vials; administered as a 1200 mg intravenous (IV) infusion once in a 3-week cycle (q3w).
RegorafenibDrug
Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in All Randomized ParticipantsTime frame: Up to 32 months
- Overall Survival (OS) of XL092 + Atezolizumab Versus Regorafenib in Randomized Non-Liver Metastases (NLM) ParticipantsTime frame: Up to 32 months
Locations
133 sites in 16 countries. Site status is shown where the registry gives one.
Exelixis Clinical Site #65
Jonesboro, Alabama
Exelixis Clinical Site #30
Phoenix, Arizona
Exelixis Clinical Site #70
Tucson, Arizona
Exelixis Clinical Site #9
Duarte, California
Exelixis Clinical Site #55
La Jolla, California
Exelixis Clinical Site #77
Los Angeles, California
Exelixis Clinical Site #105
Orange, California
Exelixis Clinical Site #80
Santa Monica, California
Exelixis Clinical Site #5
Santa Rosa, California
Exelixis Clinical Site #82
Sylmar, California
Exelixis Clinical Site #58
Torrance, California
Exelixis Clinical Site #81
Whittier, California
Exelixis Clinical Site #125
New Haven, Connecticut
Exelixis Clinical Site #16
Miami Beach, Florida
Exelixis Clinical Site #60
Orlando, Florida
Exelixis Clinical Site #4
Marietta, Georgia
Exelixis Clinical Site #3
Joliet, Illinois
Exelixis Clinical Site #102
Indianapolis, Indiana
Exelixis Clinical Site #10
Westwood, Kansas
Exelixis Clinical Site #47
Lexington, Kentucky
Exelixis Clinical Site #7
New Orleans, Louisiana
Exelixis Clinical Site #22
St Louis, Missouri
Exelixis Clinical Site #8
Billings, Montana
Exelixis Clinical Site #1
Omaha, Nebraska
Exelixis Clinical Site #15
Albuquerque, New Mexico
Exelixis Clinical Site #11
New York, New York
Exelixis Clinical Site #59
New York, New York
Exelixis Clinical Site #17
The Bronx, New York
Exelixis Clinical Site #74
Charlotte, North Carolina
Exelixis Clinical Site #6
Cincinnati, Ohio
Exelixis Clinical Site #12
Oklahoma City, Oklahoma
Exelixis Clinical Site #75
Portland, Oregon
Exelixis Clinical Site #106
Philadelphia, Pennsylvania
Exelixis Clinical Site #18
Pittsburgh, Pennsylvania
Exelixis Clinical Site #103
Pittsburgh, Pennsylvania
Exelixis Clinical Site #24
Greenville, South Carolina
Exelixis Clinical Site #56
Chattanooga, Tennessee
Exelixis Clinical Site #76
Nashville, Tennessee
Exelixis Clinical Site #133
Nashville, Tennessee
Exelixis Clinical Site #450
Fairfax, Virginia
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.